Endoscopy-based management decreases the risk of postoperative recurrences in Crohn’s disease

Table 2 Univariate analysis of risk factors for endoscopic postoperative recurrence in Crohn’s disease

	Median time to endoscopic POR (mo)	HR [95%CI]	P value
Age		1.00 [0.99-1.00]	0.2
Age
< 35 yr	41.4	Reference
≥ 35 yr	24.0	1.26 [0.86-1.84]	0.23
Age at diagnosis
≤ 16 yr	38.1	Reference
16-40 yr	34.6	0.88 [0.47-1.67]	0.71
≥ 40 yr	17.6	1.41 [0.60-2.63]	0.53
Tobacco use
Non-smoker	38.1	Reference
Active smoker	27.9	1.28 [0.77-1.70]	0.49
Previous intestinal resection
No	43.5	Reference
Yes	20.5	1.22 [0.98-2.15]	0.06
Total resection length > 50 cm
No	20.5	Reference
Yes	30.2	0.98 [0.56-1.73]	0.7
Disease behavior (Montreal classification)
B1	-	Reference
B2	43.5	1.30 [0.46-3.75]	0.62
B3	22.6	1.34 [0.47-3.80]	0.58
Fistulizing Crohn’s disease (B3)
No	29.3	Reference
Yes	22.6	1.06 [0.73-1.53]	0.75
Perianal lesions
No	34.6	Reference
Yes	19.2	1.18 [0.82-1.71]	0.37
Type of perianal lesions
Non-fistulizing lesions	33.4	Reference
Fistula, abscess	20.5	1.10 [0.75-1.60]	0.23
Disease duration		1.00 [0.99-1.01]	0.77
Ileal resection > 50 cm
No	25.9	Reference
Yes	114.5	0.58 [0.21-1.60]	0.29
Prior exposure to anti-TNF therapy before surgery
No	41.5	Reference
Yes	8.0	3.91 [1.80-5.90]	< 0.001
Thiopurines therapy in prevention of endoscopic postoperative recurrence
No	43.5	Reference
Yes	43.7	1.07 [0.69-1.65]	0.75
Anti-TNF therapy in prevention of endoscopic postoperative recurrence
No	41.4	Reference
Yes	20.5	1.28 [0.78-2.13]	0.55
Period of surgery
1986-1999		Reference
2000-2015		1.00 [0.54-1.84]	0.99

CRP: C-reactive protein; TNF: Tumor necrosis factor.